Drug Pricing Initiatives: US lawmakers continue to debate the drug pricing measure introduced by House Democrats, H.R. 3 (the Elijah E. Cummings Lower Drug Costs Now Act). Among other things, H.R. 3 would empower the Department of Health and Human Services (HHS) to negotiate drug prices directly with manufacturers. On July 20, 2021, the Center for American Progress (CAP) published an analysis of the impacts of this provision, including details on how specific drugs may be affected.